SecBot SecBot
Biotech Drug Report Generated Oct 24, 2026

ARGX-124

ARGX·ARGENX SE
NEUTRAL
Drug Impact Rating1/10
Trial phase
Not stated
Time to market
Not stated
Why 1/10
No hard, dated catalyst exists for "ARGX-124" because the drug could not be identified in any available source. With no identifiable drug, no catalyst can be scored.
⚠ Few sources Few sources were found for this drug. Treat the rating as low-confidence and verify against the cited sources.
Actionable Insight NEUTRAL

"ARGX-124" could not be identified as an existing drug candidate in any public or internal database. Investors should verify the correct drug name or code before making any trading decisions. Argenx's known near-term catalysts are the myositis Phase 3 readout (expected Q3 2026) and the MMN Phase 3 readout (expected Q4 2026) for its approved/commercial-stage assets.

Price Chart

Loading chart...

Executive Summary

No evidence of a drug called "ARGX-124" was found in any available source. Argenx SE (Nasdaq: ARGX) is a commercial-stage immunology company whose known pipeline includes efgartigimod (VYVGART, approved), ARGX-117 (Phase 2, multifocal motor neuropathy), ARGX-119 (Phase 2, ALS, terminated), empasiprubart (Phase 2/3), and FB102 (anti-CD122, preclinical/Phase 1 via Forte acquisition). The code "ARGX-124" does not appear in clinical trial registries, FDA records, press releases, SEC filings, or any internal database. It may be a very early preclinical candidate not yet publicly disclosed, a discontinued program, or a typo.

How It Works

Unknown, drug candidate could not be identified.

Trial Status

No clinical trial records found for "ARGX-124" in any available database.

The Two-Sided Case

▲ Bull Case1
No information available, drug could not be found in any available source.
▼ Bear Case1
No information available, drug could not be found in any available source.

Upcoming Catalysts

  • ["No catalysts identified for "ARGX-124" because the drug could not be identified."]

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ARGENX SE 6-K ARGX ·Originating report